ArticleCancer cell international2018
Antitumor activity of arsenite in combination with tetrandrine against human breast cancer cell line MDA-MB-231 in vitro and in vivo.
Article in Cancer cell international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Breast Cancer and Arsenic Anticancer Effects: Systematic Review of the Experimental Data fromBioMed research international · 2022Pooled it
- Improving the Hydrophilicity of the Drugs Paclitaxel, Violacein, and Tetrandrine Using Carbon-Based Quantum Dots.Nanomaterials (Basel, Switzerland) · 2026Article
- Review
- Tetrandrine for Targeting Therapy Resistance in Cancer.Current topics in medicinal chemistry · 2024Review
- Altered Regulation of the Glucose Transporter GLUT3 in PRDX1 Null Cells Caused Hypersensitivity to Arsenite.Cells · 2023Article
- Natural-Product-Derived Adjunctive Treatments to Conventional Therapy and Their Immunoregulatory Activities in Triple-Negative Breast Cancer.Molecules (Basel, Switzerland) · 2023Review
- Cytotoxic Effects of Darinaparsin, a Novel Organic Arsenical, against Human Leukemia Cells.International journal of molecular sciences · 2023Article
- Enhanced Cytotoxic Effects of Arenite in Combination with Active Bufadienolide Compounds against Human Glioblastoma Cell Line U-87.Molecules (Basel, Switzerland) · 2022Article
- Natural Small Molecules in Breast Cancer Treatment: Understandings from a Therapeutic Viewpoint.Molecules (Basel, Switzerland) · 2022Review
- Progress on structural modification of Tetrandrine with wide range of pharmacological activities.Frontiers in pharmacology · 2022Review
- The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer.Nutrients · 2021Review
- Cytotoxic Effects of Hellebrigenin and Arenobufagin Against Human Breast Cancer Cells.Frontiers in oncology · 2021Article
- Cytotoxic Effects of Arsenite in Combination With Gamabufotalin Against Human Glioblastoma Cell Lines.Frontiers in oncology · 2021Article
- Development, optimization, and evaluation of PEGylated brucine-loaded PLGA nanoparticles.Drug delivery · 2020Article
- Anti-Tumor Effects of Sodium Meta-Arsenite in Glioblastoma Cells with Higher Akt Activities.International journal of molecular sciences · 2020Article
- Role of natural compounds in preventing and treating breast cancer.Frontiers in bioscience (Scholar edition) · 2020Article
- JNK and Autophagy Independently Contributed to Cytotoxicity of Arsenite combined With TetrandrineFrontiers in pharmacology · 2020Article
- Antitumor activity of tetrandrine citrate in human glioma U87 cells in vitro and in vivo.Oncology reports · 2019Article
- Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents.American journal of cancer research · 2019Review
- Differentiation induction of human breast cancer cells by arsenite in combination with tetrandrine.American journal of translational research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTriple-negative breast cancer (TNBC) is one of the most difficult subtypes of breast cancer to treat due to its aggressive, metastatic behavior, and a lack of a targeted therapy. Trivalent arsenic derivatives (arsenite, As
methodsCytotoxicity was evaluated using cell viability, lactate dehydrogenase leakage and cell cycle assay. Alterations of genes related to cell proliferation and death were analyzed using western blotting. In vivo antitumor activity of As
resultsSynergistic cytotoxic effects of two drugs were observed in the cells. In vivo study also showed that co-administration of As
conclusionsS-phase arrest, autophagic and necrotic cell death contribute to the cytocidal effects of the combined regimen of As
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.